Cybin INC. (HELP) — SEC Filings

Q: What are the key financial highlights for Cybin INC.?

Key financial highlights for Cybin INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: What is the investment thesis for HELP?

The investment thesis for HELP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings filed by Cybin INC..

Q: Who are the key executives at Cybin INC.?

Key executives at Cybin INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Cybin INC. stock?

Risk factors for Cybin INC. (HELP) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Cybin INC.?

Forward-looking statements and predictions from Cybin INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Cybin INC.. Recent 6-K filing on Apr 16, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Cybin INC. on SEC EDGAR

Overview

Cybin INC. (HELP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 31, 2025: Cybin Inc. filed a Form 6-K on December 31, 2025, reporting for the month of December 2025. The filing incorporates Exhibit 99.1 into its Form F-10 Registration Statement (File No. 333-292294). The company is incorporated in A6 and its fiscal year ends on March 31.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 7 bullish, 43 neutral. The dominant filing sentiment for Cybin INC. is neutral.

Filing Type Overview

Cybin INC. (HELP) has filed 50 6-K with the SEC between Jan 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (50)

6-K Filing — 6-K · Apr 16, 2026
Cybin Inc. Files 6-K, Incorporates Exhibit into F-10 — 6-K · Dec 31, 2025 Risk: low
Cybin Inc. filed a Form 6-K on December 31, 2025, reporting for the month of December 2025. The filing incorporates Exhibit 99.1 into its Form F-10 Registration
Cybin Inc. Files 6-K, Incorporates Exhibits — 6-K · Dec 30, 2025 Risk: low
Cybin Inc. filed a Form 6-K on December 30, 2025, to incorporate by reference Exhibits 99.1 and 99.2 into its existing Registration Statement on Form F-10 (File
Cybin Inc. Files 6-K, Announces Nasdaq Transfer — 6-K · Dec 22, 2025 Risk: medium
Cybin Inc. filed a Form 6-K on December 22, 2025, reporting on events for the month of December 2025. The filing includes a news release dated December 18, 2025
6-K Filing — 6-K · Dec 18, 2025
6-K Filing — 6-K · Nov 26, 2025
Cybin Inc. Files Form 6-K, Incorporates Exhibits — 6-K · Nov 13, 2025 Risk: low
Cybin Inc. filed a Form 6-K on November 13, 2025, incorporating Exhibits 99.1 and 99.2 into its existing Registration Statement on Form F-10 (File No. 333-28913
6-K Filing — 6-K · Nov 12, 2025
Cybin Inc. Files 6-K, Announces News Release — 6-K · Nov 6, 2025 Risk: low
Cybin Inc. filed a Form 6-K on November 6, 2025, to report a news release dated November 6, 2025. The news release, attached as Exhibit 99.1, is titled 'Cybin t
Cybin Inc. to Participate in Guggenheim Healthcare Conference — 6-K · Nov 5, 2025 Risk: low
Cybin Inc. filed a Form 6-K on November 5, 2025, reporting its participation in the Guggenheim Healthcare Conference. The filing includes a news release dated N
6-K Filing — 6-K · Nov 3, 2025
Cybin Inc. Files October 2025 Report on Form 6-K — 6-K · Oct 31, 2025 Risk: low
Cybin Inc. filed a Form 6-K on October 31, 2025, reporting for the month of October 2025. The filing includes a news release dated October 31, 2025, as Exhibit
Cybin Inc. Files 6-K, Incorporates Exhibits into F-10 — 6-K · Oct 29, 2025 Risk: medium
Cybin Inc. filed a Form 6-K on October 29, 2025, incorporating by reference exhibits 99.1 through 99.5 into its Registration Statement on Form F-10 (File No. 33
Cybin Secures $175M Credit Facility — 6-K · Oct 28, 2025 Risk: medium
On October 28, 2025, Cybin Inc. announced a new $175 million revolving credit facility. This facility is provided by an affiliate of Fortress Investment Group L
Cybin Inc. Files 6-K Report — 6-K · Sep 23, 2025 Risk: low
Cybin Inc. filed a Form 6-K on September 23, 2025, reporting on its activities for the month of September 2025. The filing includes a news release dated Septemb
Cybin Inc. Files 6-K, Incorporates Exhibit into F-10 — 6-K · Sep 18, 2025 Risk: low
Cybin Inc. filed a Form 6-K on September 18, 2025, incorporating Exhibit 99.1 into its F-10 Registration Statement (File No. 333-289139). This filing is for the
Cybin Inc. Files 6-K, Incorporates Exhibit into F-10 — 6-K · Sep 17, 2025 Risk: low
Cybin Inc. filed a Form 6-K on September 17, 2025, incorporating Exhibit 99.1 into its F-10 Registration Statement (File No. 333-284173). This filing relates to
Cybin Inc. Files 6-K, Participates in Cowen Event — 6-K · Sep 11, 2025 Risk: low
On September 11, 2025, Cybin Inc. filed a Form 6-K report. This filing includes a news release dated September 11, 2025, announcing Cybin's participation in the
Cybin Inc. Files 6-K, Announces Trial Enrollment Completion — 6-K · Sep 9, 2025 Risk: medium
On September 8, 2025, Cybin Inc. filed a Form 6-K report. This filing includes a news release dated September 8, 2025, announcing the completion of a clinical t
Cybin Inc. Files Form 6-K on Sept 4, 2025 — 6-K · Sep 4, 2025 Risk: low
On September 4, 2025, Cybin Inc. filed a Form 6-K, reporting a news release dated September 4, 2025. The filing indicates Cybin Inc. is a pharmaceutical prepara
Cybin Inc. Files 6-K, CFO Greg Cavers Signs — 6-K · Sep 3, 2025 Risk: low
Cybin Inc. filed a Form 6-K on September 3, 2025, reporting a news release dated the same day. The filing indicates Cybin Inc. is a pharmaceutical preparations
Cybin Inc. Files 6-K, Announces Leadership Changes — 6-K · Sep 2, 2025 Risk: low
On September 2, 2025, Cybin Inc. filed a Form 6-K, reporting on its activities for the month of September 2025. The filing includes a news release dated Septemb
Cybin Inc. Gets Australian TGA Approval for MDD Trial — 6-K · Aug 26, 2025 Risk: medium
Cybin Inc. filed a Form 6-K on August 26, 2025, reporting a news release dated August 26, 2025. The news release, attached as Exhibit 99.1, details Cybin's rece
Cybin Inc. Files Form 6-K with News Release and Voting Results — 6-K · Aug 19, 2025 Risk: low
On August 18, 2025, Cybin Inc. filed a Form 6-K report with the SEC. This filing includes a news release dated August 18, 2025, and a report of voting results.
Cybin Inc. Files 6-K, Incorporates Exhibits into F-10 — 6-K · Aug 14, 2025 Risk: low
Cybin Inc. filed a Form 6-K on August 14, 2025, reporting for the period ending June 30, 2025. The filing incorporates by reference exhibits 99.1, 99.2, and 99.
Cybin Inc. Files 6-K, Incorporates Exhibits into Registration Statement — 6-K · Aug 13, 2025 Risk: low
Cybin Inc. filed a Form 6-K on August 13, 2025, incorporating Exhibits 99.1 and 99.2 into its existing Registration Statement on Form F-10 (File No. 333-289139)
Cybin Inc. Secures European Market Approval — 6-K · Aug 7, 2025 Risk: medium
On August 7, 2025, Cybin Inc. announced it received European market approval for its novel psychedelic treatment. This approval is a significant step for the co
Cybin Inc. to Participate in Canaccord Growth Conference — 6-K · Aug 6, 2025 Risk: low
Cybin Inc. filed a Form 6-K on August 6, 2025, announcing its participation in the Canaccord Growth Conference. The filing includes a news release dated August
Cybin Inc. Files 6-K, Incorporates Exhibit 99.1 — 6-K · Jul 28, 2025 Risk: low
Cybin Inc. filed a Form 6-K on July 28, 2025, incorporating Exhibit 99.1 into its existing Registration Statement on Form F-10 (File No. 333-284173). This filin
Cybin Gets UK Green Light for Psychedelic Depression Trial — 6-K · Jul 17, 2025 Risk: medium
Cybin Inc. announced on July 17, 2025, that it has received a Clinical Trial Authorisation (CTA) from the UK's Medicines and Healthcare products Regulatory Agen
Cybin Inc. Files 6-K, Incorporates Exhibit into F-10 — 6-K · Jul 14, 2025 Risk: low
Cybin Inc. filed a Form 6-K on July 14, 2025, to incorporate Exhibit 99.1 into its F-10 Registration Statement (File No. 333-284173). This filing is routine for
Cybin Inc. Files Form 6-K, Incorporates Exhibit — 6-K · Jul 10, 2025 Risk: low
Cybin Inc. filed a Form 6-K on July 10, 2025, incorporating Exhibit 99.1 into its F-10 Registration Statement (File No. 333-284173). This filing is for the mont
Cybin Inc. Files 6-K, Incorporates Exhibit 99.1 — 6-K · Jul 1, 2025 Risk: low
Cybin Inc. filed a Form 6-K on July 1, 2025, for the month ending June 30, 2025. This filing incorporates by reference Exhibit 99.1 into its Form F-10 Registrat
Cybin Inc. Files 6-K with Corporate Update — 6-K · Jun 13, 2025 Risk: low
On June 13, 2025, Cybin Inc. filed a Form 6-K report. This filing includes a news release dated June 13, 2025, providing a corporate update. The report is signe
Cybin Inc. to Present at H.C. Wainwright Conference — 6-K · Jun 12, 2025 Risk: medium
Cybin Inc. announced on June 12, 2025, its participation in the H.C. Wainwright Neo-Securities Conference. CEO Doug Drysdale is scheduled to present on June 17,
Cybin Inc. to Present at Stifel Virtual Healthcare Conference — 6-K · Jun 11, 2025 Risk: low
Cybin Inc. announced on June 11, 2025, that it will participate in the Stifel 2025 Virtual Healthcare Conference. The company, headquartered at 100 King Street
Cybin Secures European Patent for CY003 — 6-K · Jun 3, 2025 Risk: medium
On June 3, 2025, Cybin Inc. filed a Form 6-K report. This filing includes a news release dated June 3, 2025, announcing additional patent protection for its deu
Cybin Inc. Files 6-K, CEO to Speak at Investor Conference — 6-K · May 22, 2025 Risk: low
Cybin Inc. filed a Form 6-K on May 22, 2025, reporting its participation in the Water Tower Research Virtual Investor Conference. The company's CEO, Doug Drysda
Cybin Inc. Files 6-K, Reacts to FDA Commission — 6-K · May 20, 2025 Risk: medium
Cybin Inc. filed a Form 6-K on May 20, 2025, reporting a news release dated May 20, 2025. The news release, attached as Exhibit 99.1, concerns Cybin's positive
Cybin Inc. Engages Thermo Fisher Scientific — 6-K · May 15, 2025 Risk: medium
Cybin Inc. filed a Form 6-K on May 15, 2025, reporting a news release dated May 15, 2025. This news release, attached as Exhibit 99.1, details Cybin's engagemen
Cybin Inc. to Present at Atai Life Sciences AGPS Showcase — 6-K · May 14, 2025 Risk: low
Cybin Inc. filed a Form 6-K on May 14, 2025, to report its participation in the Atai Life Sciences AGPS Showcase. The filing includes a news release dated May 1
Cybin Inc. Secures Additional U.S. Patent — 6-K · May 8, 2025 Risk: low
Cybin Inc. filed a Form 6-K on May 8, 2025, reporting a news release dated May 8, 2025, regarding an additional U.S. patent. The company, headquartered in Toron
Cybin CEO to Speak at Oppenheimer Healthcare Conference — 6-K · May 1, 2025 Risk: medium
Cybin Inc. announced on May 1, 2025, its participation in the 28th Annual Oppenheimer & Co. Inc. Healthcare Conference. CEO Doug Drysdale is scheduled to partic
Cybin Inc. Files 6-K with Clinical Program Update — 6-K · Apr 23, 2025 Risk: medium
On April 23, 2025, Cybin Inc. filed a Form 6-K, reporting a news release dated April 23, 2025. The news release, attached as Exhibit 99.1, likely contains impor
Cybin Inc. Announces Partnership with Osm — 6-K · Apr 21, 2025 Risk: medium
On April 21, 2025, Cybin Inc. filed a Form 6-K report. This filing includes a news release dated April 21, 2025, announcing a partnership with Osm. The news rel
Cybin Inc. Files 6-K Report, Incorporates Exhibit 99.1 — 6-K · Feb 14, 2025 Risk: low
Cybin Inc. filed a Form 6-K on February 14, 2025, to report information for the month of February 2025. The filing incorporates Exhibit 99.1 by reference into i
Cybin Inc. Files 6-K, Incorporates Exhibits into F-10 — 6-K · Feb 11, 2025 Risk: low
Cybin Inc. filed a Form 6-K on February 11, 2025, to report information for the month of February 2025. This filing incorporates by reference Exhibits 99.1 and
Cybin Inc. Files 6-K, Incorporates Exhibits — 6-K · Feb 11, 2025 Risk: low
Cybin Inc. filed a Form 6-K on February 11, 2025, incorporating by reference exhibits 99.1, 99.2, and 99.5 into its existing Registration Statement on Form F-10
Cybin Inc. Partners for CYB003 Clinical Trials — 6-K · Jan 15, 2025 Risk: medium
On January 15, 2025, Cybin Inc. filed a Form 6-K, announcing a strategic clinical development collaboration with a major pharmaceutical company. This collaborat
Cybin Inc. Files 6-K with January 13th News Release — 6-K · Jan 13, 2025 Risk: low
Cybin Inc. filed a Form 6-K on January 13, 2025, reporting its status as a foreign private issuer. The filing includes a news release dated January 13, 2025, wh

Risk Profile

Risk Assessment: Of HELP's 45 recent filings, 0 were flagged as high-risk, 15 as medium-risk, and 30 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Greg Cavers
Doug Drysdale

Top Tags

news-release (15) · filing (13) · sec-filing (12) · registration-statement (8) · registration (7) · conference-participation (6) · pharmaceuticals (6) · 6-K (5) · regulatory-filing (4) · corporate-update (4)

Key Numbers

SEC File Number: 001-40673 — Identifies Cybin Inc.'s filings with the SEC.
Registration Statement File Number: 333-292294 — Refers to the active F-10 registration statement where exhibits are incorporated.
Exhibits Incorporated: 99.1, 99.2, 99.3, 99.4 and 99.5 — These exhibits are incorporated by reference into the company's Form F-10 registration statement.
Revolving Credit Facility: $175M — Provides significant liquidity for corporate purposes and strategic initiatives.
Maturity Date: October 28, 2028 — Sets the timeframe for repayment of the credit facility.
Form F-10 File Number: 333-284173 — Reference for the incorporated registration statement.
Trial Phase: Phase 2 — The trial for CYB003 in Australia is entering Phase 2.
Commission File Number: 001-40673 — Cybin Inc.'s SEC file number.
Clinical Trial Phase: Phase 2b — Study for CYB003 in MDD
Participants: 120 — Expected enrollment for the Phase 2b study

Related Companies

CYBN

Frequently Asked Questions

What are the latest SEC filings for Cybin INC. (HELP)?

Cybin INC. has 50 recent SEC filings from Jan 2025 to Apr 2026, including 50 6-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of HELP filings?

Across 50 filings, the sentiment breakdown is: 7 bullish, 43 neutral. The dominant sentiment is neutral.

Where can I find Cybin INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Cybin INC. (HELP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Cybin INC.?

Financial highlights for Cybin INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for HELP?

Investment thesis data for HELP will be available once enriched filings are processed.

Who are the key executives at Cybin INC.?

Key executives identified across Cybin INC.'s filings include Greg Cavers, Doug Drysdale.

What are the main risk factors for Cybin INC. stock?

Of HELP's 45 assessed filings, 0 were flagged high-risk, 15 medium-risk, and 30 low-risk.

What are recent predictions and forward guidance from Cybin INC.?

Forward guidance and predictions for Cybin INC. are extracted from SEC filings as they are enriched.